ABSTRACT Coronavirus disease 2019 (COVID-19) originated in the city of Wuhan, Hubei
Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is …

Expectations on mesenchymal stem cell (MSC) treatment are high, especially in the fields of
sepsis, transplant medicine, and autoimmune diseases. Various pre-clinical studies have …

Multipotent mesenchymal stromal cells (MSCs) ameliorate a wide range of diseases in
preclinical models, but the lack of clarity around their mechanisms of action has impeded …

Abstract As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019)
pandemic has swept through 213 countries and infected more than 1,870,000 individuals …

Acute respiratory distress syndrome (ARDS) is a syndrome of acute respiratory failure
caused by noncardiogenic pulmonary edema. Despite five decades of basic and clinical …

Earlier research primarily attributed the effects of mesenchymal stem cell (MSC) therapies to
their capacity for local engrafting and differentiating into multiple tissue types. However …

Rationale: Acute respiratory distress syndrome (ARDS) remains a major cause of respiratory
failure in critically ill patients. Mesenchymal stromal cells (MSCs) are a promising candidate …

Improving the immunomodulatory efficacy of mesenchymal stem cells (MSCs) through
pretreatment with pro-inflammatory cytokines is an evolving field of investigation. However …

The clinical description that defines acute lung injury (ALI) has been around for more than
50 years. The clinical picture has carried many different definitions, but what was known as …

Mesenchymal stromal cells (MSC) have been reported to improve bacterial clearance in
preclinical models of Acute Respiratory Distress Syndrome (ARDS) and sepsis. The …